单克隆抗体在肿瘤治疗中的应用  

Monoclonal Antibody Therapy of Cancer

作　　者：谷欣[1] 陈国胜[2] 张想竹[1] 

机构地区：[1]安阳工学院,河南安阳455000 [2]新乡师范高等专科学校化学系,河南新乡453000

出　　处：《安阳师范学院学报》2007年第5期71-74,共4页Journal of Anyang Normal University

摘　　要：随着一些单克隆抗体获准被应用于临床,单抗在肿瘤治疗中的运用得到了快速发展。其中代表性的有抗血管内皮生长因子的单抗bevacizumab(Avastin),和抗表皮生长因子的cetuximab(Erbitux)。结合常规的化疗,bevacizumab能够显著延长结肠癌、乳腺癌及肺癌患者的生命。Cetuximab无论与化疗联合使用或单独使用对于对化疗有耐药性的结肠癌直肠癌均有显著的临床意义。The most significant recent advances in the application of monoclonal antibodies （mAbs） to oncology have been the introduction and approval of bevacizumab （Avastin）, an anti-vascular endothelial growth factor antibody, and of cetuximab （Erhitux）, an anti-epidermal growth factor antibody. In combination with standard chemotherapy regimens, hevacizumab significantly prolongs the survival of patients with metastatic cancers of the colorectum, breast and lung. Cetuximab, used alone or with salvage chemotherapy, produces clinically meaningful anti - tumor responses in patients with chemotherapy - refractory cancers of the colon and rectum. These exciting recent results provide optimism for the development of mAbs that bind novel targets, exploit novel mechanisms of action or possess improved tumor targeting.

关 键 词：单克隆抗体 癌症 

分 类 号：Q813.2[生物学—生物工程]